Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.
Rea
D
D
Etienne
G
G
Corm
S
S
Cony-Makhoul
P
P
Gardembas
M
M
Legros
L
L
Dubruille
V
V
Hayette
S
S
Mahon
F-X
FX
Cayuela
J-M
JM
Nicolini
F E
FE
D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D020714:Maximum Tolerated Dose; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate